GuardantINFORM data meet multiple research needs and use cases to advance your oncology portfolio.

Early Stage

Study biomarker prevalence, treatment landscape, and characteristics across
any solid tumor target population

Disease Prevalence
Validation

Differentiated
Biomarker Discovery

Study all mutated genes in a pathway
to develop a comprehensive and
robust biomarker definition

Compare rwOS, rwPFS, rwTTD, and
rwTTNT across different therapies
and/or therapy classes

Clinical Development

Unmet Need Characterization

Trial Comparator Arm

Evaluate treatment journeys and
outcomes in trial criteria-matched
real-world population

Commercial Launch

Real-time identification of therapy-
eligible population to support launch strategy and planning

Commercial Alerts

Evidence Generation

Study therapy in real world and
compare to similar therapies to show superior efficacy and safety profile

rwOS, real-world overall survival; rwPFS, real-world progression-free survival; rwTTD, real-world time to discontinuation; rwTTNT, real-world time to next treatment.